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Abstract
Background: There are now effective drugs to prevent cardiovascular disease and guidelines recommend their
use. Patients do not always choose to accept preventive medication at levels of risk reduction recommended in
guidelines. The purpose of the study was to identify and explore the attitudes of patients and general practitioners
towards preventative medication for cardiovascular disease (CVD) after they have received information about it; to
identify implications for practice and prescribing.
Methods: Qualitative interviews with GPs and patients following presentation of in depth information about CVD
risks and the absolute effects of medication. Setting: GP practices in Birmingham, United Kingdom.
Results: In both populations: wide variation on attitudes to preventative medication; concerns about unnecessary
drug taking & side effects; preferring to consider lifestyle changes first. In patient population: whatever their
attitudes to medication were, the vast majority explained that they would ultimately do what their GP
recommended; there was some misunderstanding of the distinction between curative and preventative
medication. A common theme was the degree of trust in their doctors’ judgement and recommendations, which
contrasted with scepticism of the role of pharmaceutical companies and academics. Scepticism in guidelines was
also common among doctors although many nevertheless recommended treatment for their patients
Conclusions: A guideline approach to prescribing preventative medication could be against the interests and
preferences of the patient. GPs must take extra care to explain what preventative medication is and why it is
recommended, attempt to discern preferences and make recommendations balancing these potentially conflicting
concerns.
Background
Cardiovascular disease (CVD) is the largest cause of pre-
mature death in the UK with a particularly heavy burden
on South Asian ethnic groups [1]. There are now a num-
ber of drugs that prevent CVD and as a result there are
complex questions about whether patients should start
medication. Clinical trials have indicated that treatment
with statins reduces the probability of developing cardio-
vascular disease by about 30% of the pre treatment
probability [2,3]. A reduction in blood pressure of 10
mmHg reduces probability by a similar amount [4]. This
is relative reduction in cardiovascular risk; the absolute
benefits of treatment therefore depend on pre treatment
probability of cardiovascular disease. A number of studies
have indicated that patients prefer to take medication
only when the degree of risk reduction is somewhat
greater than the risk reduction at which clinicians and
clinical guidelines recommend preventive treatment
[5-8]. By contrast, in a previous study by the authors of
this paper the majority of participants who had accepted
an invitation for cardiovascular assessment preferred to
take treatment for a degree of risk reduction much
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any medium, provided the original work is properly cited.smaller than the threshold implied in clinical guidelines.
Preferences were influenced by social class, with those
from lower socio-economic groups willing to accept
treatment for a smaller reduction in risk [9]. However,
some remain reticent about medicine taking[10] and it
has been observed that whether or not medicines are pre-
scribed for patients is often patterned by social factors,
such as age, affluence and ethnicity, although deprivation
is often the most overriding factor [11-13]. Information is
often, in a commonsensical way, considered to be key to
ensuring that prescribing is concordant but, to date, no
research has looked at patients’ and health professionals’
attitudes towards medication for the primary prevention
of CVD after receiving detailed information on risks and
absolute benefit. Our study gave patients and their GPs
detailed information about relative and absolute risk
reduction in words, numbers and using visual aids on a
PowerPoint presentation. The whole presentation took
approximately ten minutes to deliver.
The National Institute for Health and Clinical Excel-
lence (NICE) guidelines suggest that, ‘Statin therapy is
recommended as part of the management strategy for the
primary prevention of CVD for adults who have a 20% or
greater 10-year risk of developing CVD’ [14]. Risk should
be calculated using an appropriate risk calculator or by
clinical assessment, considering age, co-morbidities and
high-risk ethnic groups. It is also recommended that
individuals at greater than 20% 10-year cardiovascular
risk are treated with antihypertensives if their blood pres-
sure exceeds 140/90 mm Hg and with aspirin if they are
aged 50 years or over [15]. Concurrently, the idea of ‘con-
cordance and partnership in taking medicines’ is high on
the health policy agenda [16], based on the principle that
clinicians and patients should work together to agree a
treatment plan. The NICE guidance states, ‘the decision
whether to initiate statin therapy should be made after an
informed discussion between the responsible clinician
and the individual about the risks and benefits of statin
treatment, and taking into account additional factors
such as co-morbidities and life expectancy’[14]. Concor-
dance and seeking consent for treatment are also consid-
ered an ethical duty by the General Medical Council [17].
There is a potential confusion between whether the risk
cut-off figure or the individualised decision-making takes
priority. To compound this ambiguity for the general
practitioner, it is well known that patients often have
concerns about side effects, which are muscle pains for
statin treatment although these are reported to be infre-
quent[18] and other concerns about taking medication,
such as preference for a more ‘natural’ approach or that
it disrupts their personal or social life[19]. There is some
evidence that labelling of individuals as hypertensive or
hypercholesterolaemic affects absence from work [20].
This has been the subject of longstanding debate
although evidence for the effects of labelling on psycho-
social health remains unclear [21,22]. Indeed, concerns
have been raised about the ethics of using guidelines for
preventative medication as a basis for clinical decision-
making and a more critical presentation of the research
findings and discussion with patients has been argued for
[23]. Research from the social sciences has been instru-
mental in understanding the complexities of shared deci-
sion making and the centrality of the effective two-
way communication of information [24-29]. It may be
reasonable to assume that providing patients with more
(and clearer) information might be useful for promoting
am o r e‘informed’ and ‘concordant’ approach to
prescribing.
This study sought to explore the attitudes of both
patients and GPs towards medication for primary preven-
tion of CVD after they had received detailed information
about CVD risk and the absolute benefits of preventative
medicine. The qualitative data presented were collected
with participants who had been informed of the ‘facts’
and ‘figures’ in advance of the interview.
Methods
The data reported in this paper were collected as part of
a larger study on clinician and patient preferences for
treatment to prevent heart disease conducted in 2003
[30,31]. The study was approved by South Birmingham
[Ref 0782] and North Birmingham REC [Ref 626.01].
Patients identified as likely to be at high coronary risk
were invited for cardiovascular risk assessment in their
own general practice.
In 13 general practices, patients aged 35 to 74 without
cardiovascular disease and not currently taking preven-
tive treatments were identified from electronic primary
care records. In order to identify those most likely to be
at high risk of cardiovascular disease, patients were
ranked in descending order of age (men) and age minus
12 (women). This is because average coronary risk in
women is roughly the same as that of men 12 years
older [32,33]. This method therefore provided a list of
patients ranked by their coronary risk. In each practice,
letters were sent to highest risk patients inviting them
to attend the practice for coronary risk screening and to
participate in the research study. Further letters were
sent in descending risk order until sufficient patients
attended. This resulted in a sample of participants simi-
lar to those likely to take part in a programme of risk
screening targeted at those at highest risk.
Prior to assessment they were interviewed face-to-face
and asked to consider six scenarios representing different
levels of pre-treatment five-year coronary risk. Five-year
coronary risk was chosen because in 2003 guidelines
used five-year instead of ten-year risk[34]. A five-year
risk of 10% is approximately equivalent to a ten-year risk
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is recommended. For each scenario they were asked
hypothetically to consider whether they would take pre-
ventative medication that reduced their coronary risk by
30% of pre-treatment risk. Because the pre treatment
coronary risk varied in each scenario the effectiveness of
the drug (absolute benefit) also varied. This allowed us to
establish a threshold absolute risk reduction at which
participants judged treatment to become worthwhile.
Information was presented using decision aids [35]. This
showed the number of persons out of 100 who would be
expected to suffer a cardiovascular event in the next five
years with and without treatment. The information was
also presented in the opposite way, stating the number of
persons out of 100 who would be expected not to suffer
from a cardiovascular event in the next five years with
and without treatment. The information was presented
both in words and using a vertical bar on a graph where
the difference in height of the bar with and without treat-
ment indicating the reduction in risk.
At the end of each presentation, participants were
given a ‘comprehension test’ on the numerical risk infor-
mation by providing two additional scenarios. For these
participants were asked to choose between two otherwise
identical treatments that reduced coronary risk by differ-
ent amounts. Participants who on both occasions pre-
ferred the treatment that reduced risk more were judged
to have understood the numerical information.
Following assessment by their general practitioner
they were interviewed again. At the second interview
patients were informed of their real five-year risk and
asked again whether if they were offered treatment they
would accept it. Information was again presented in
words and numbers and visually using decision aids.
Preferences were considered to be consistent if their
preference at second interview was consistent with the
implied threshold risk reduction at first interview.
Responses were generally consistent from first to second
interview. While age, sex, education and drug treatment
history did not affect preferences, lower socio-economic
status was associated with preferring treatment at lower
risk [36].
In addition to this preference data, supplementary
qualitative data were collected from a purposive sub-
sample of the patients (reflecting those with demo-
graphic characteristics likely to be at high risk) to
understand their decisions and preferences in more
depth and to get their opinions on the information that
was presented to them. At the end of the project GPs in
participating practices were also questioned on their
preferences in relation to the different hypothetical risk
scenarios and asked supplementary qualitative questions.
These data were analysed using inductive coding and
two analytical frameworks were developed which
explored, for example, attitudes to medication and clini-
cal decision making. While separate frameworks were
developed for the patients and the GPs, there were
some overlapping themes. For the patients, the qualita-
tive data was cross-tabulated in the analytical framework
with the quantitative data on whether they understood
the information and at what risk level they would accept
treatment.
Qualitative data were collected after both the first and
follow-up interviews for pref e r e n c ed a t af o ras u b - s a m -
ple of 17 patients. We checked that 17 was a sufficient
number for saturation by conducting response validation
with 5 additional participants. A single qualitative inter-
view was conducted with all 13 GPs who participated in
the study.
The key areas that we wanted to explore with patients
were attitudes to taking medication generally and speci-
fically in relation to CVD prevention, whether the risk
and benefit information provided in the study was help-
ful and desirable in decision-making and finally, whose
decision the patients felt it should be about whether to
take the preventative medication. With the general prac-
titioners, we explored their general views on prevention
of CVD, including the role they felt that medication
played, and their attitudes to accepting medication
themselves if their own risk level was above the thresh-
old at which they would prescribe for their patients.
Transcripts were coded inductively. The key themes
that emerged from the data showed a great deal of
diversity in the responses for both the patients and clini-
cians. The data presented here reflect that range of
responses and highlight contradictory attitudes within
the sample. All comments quoted are anonymised but
attributed by employment, ethnic identity, gender and
age. For the patients, their actual 5 year risk score (cal-
culated using the Framingham coronary risk equation
because at the time of the study this was used to deter-
mine treatment eligibility and a coronary risk calculator
had been incorporated into electronic primary care data-
bases) and the threshold at which they would accept
preventative treatment are included. These last two fac-
tors are not included for the GPs as their risk scores
were not calculated and they were not asked the ques-
tion about at what level of risk they would personally
accept treatment as part of the quantitative data collec-
tion (although it was included in the qualitative topic
guide, as above). They were asked at what level they
would prescribe for their patients, which is included.
Results
GP and patient age and ethnic characteristics are
described in Table 1.
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Overall, patients were cautious about taking medication,
many indicating that they preferred to keep medication
to a minimum, but that they would if it was necessary
for a condition they had or if the doctor recommended
it. There was no simple correspondence between the
level at which the patients would accept medication and
their attitudes to it. Patients who would accept medica-
tion at both the lowest and highest levels of risk that
they were asked about (3%-40% risk) had a range of
positive and negative attitudes.
The largest proportion of interviewees expressed con-
cerns about taking medication, indicating that is was a
‘last resort’ or that their attitude would depend on
whether the condition was ‘life-threatening’.M o s to f
these talked about their preference for making lifestyle
changes first.
‘At the moment I am gradually reducing weight as
one of the ways to take the strain off me. I would
rather do other things in lifestyle rather than take
medication but I’ve got no objection to medication if
that’s the only way or the best way’.[ R e t i r e d
designer of engineering tools, White British male,
65, 7% risk, > 30% threshold]
Of this group, some expressed their concern about the
effects of tablets on their bodies and expressed concerns
about taking medication. The two major concerns were
that medication could be addictive and that there might
be as-yet-unknown side effects of this medication. These
concerns are can be understood in the context of recog-
nised drug side effects, information they are likely to
have been exposed to in the media and through their
own or their family and friends’ experiences, as this
respondent’s comments show:
‘Simple things like taking aspirin; you don’tk n o w
what you’re doing to your stomach... My wife was
violently sick when she had our first daughter and
that was when they were dishing out Thalidomide...
we’ve got a lovely daughter [but] had [she] have
took Thalidomide then what would [have hap-
pened?]...Well it might cause something else. One of
my neighbours has arthritis and when these arthritic
tablets first came out, one of his friends has stomach
bleeds taking them. They cause more trouble than
they cure!’ [Project Manager, White British male, 61,
6% risk, 20% threshold]
Others expressed their concern about medication by
expressing their preferences for a more ‘natural’
approach and talking about the body’s self-healing capa-
city, as these two participants explained:
‘[My niece] is into health foods and things... and I
agree with her. Tablets are fighting something inside
which your body ought to be able to do itself’.
[Retired Civil Servant, White British female, 71, 10%
risk, 3% threshold].
’I fs o m e o n eo f f e r e dm ea na l t e r n a t i v em e d i c i n e . . .
natural stuff then I would be quite prepared to try
those’. [Retired building surveyor, White British
male, 71, 12% risk 3% threshold]
A small group of patient respondents expressed unre-
served support for medication (although sometimes also
explaining that this should happen alongside lifestyle
change), for instance:
‘Anything to try and prevent, I mean a lot of my
friends have died from heart attacks so I’mc e r t a i n l y
in favour of trying to prevent it with any means’
[Retired manager in motor trade, White British
male, 72, 12% risk, 3% threshold].
A number of the patients presented a more ambiva-
lent view, for example:
‘I’mn o tat a b l e tt a k e ru n l e s st h e r e ’s a real need ...
but if I have to take tablets for any reason I will ...
just be sensible... lead a sensible life’ [Electrical
draftsman, White British male, 72, 13% risk, 40%
threshold]
‘If it is going to extend my life or make it easier for
me to do things then great I’ma l lf o ri t. . .[ b u t ]
whatever you are doing you ... are going to get some
slight side effects ... I don’t like taking pills or any-
thing’ [Retired Toolmaker, White British male, 73,
11% risk, 3% threshold]
Table 1 Age, gender and ethnic characteristics of the
study participants
Patients GPs
Age 40-49 1 6
50-59 2 6
60-69 8 1
70-79 6 0
Ethnicity White British 9 5
White Irish 4 0
Asian (Indian or other) 4 7
Other 0 1
Gender Male 15 12
Female 2 1
TOTAL 17 13
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The overwhelming majority, irrespective of their atti-
tudes to medication and even if they had said in the
interview that they would only accept treatment at the
highest risk levels, explained that, in the final instance,
they would do whatever the doctor recommended. In
explaining this attitude, they tended to appeal to ideas
of the altruism of doctors and their greater knowledge
about health and disease.
‘The doctor is doing his own job isn’th e ?W ed o n ’t
know how to cure it. He knows better than us... so
you ought to listen to what he says. If I had to go
and see him and he says take these tablets then I
have got no choice, I should take it’ [Retired chemi-
cal process worker, Asian Indian male, 64, 15% risk,
3% threshold]
’I think the doctor should make the decision, they
know more don’t they, that’s the way I look at it.
They should know best.’ [Retired hairdresser, White
Irish female, 72, 7% risk, 3% threshold]
One respondent also drew comparisons between his
expertise and that of the doctor.
‘Because he knows what he is doing. It is for my
benefit. If he thinks it’s a good idea I would take his
advice; it’s the same as if he came to me and wanted
something in steel or aluminium, I would expect
h i mt of o l l o wm ya d v i c e .Ik n o ww h a tIa mo n
about the same as I expect him to know what he is
on about.’ [Retired toolmaker, White British male,
73, 11% risk, 3% threshold]
It is worth noting that the assumption that prevention
of CVD was a desirable outcome was not one shared by
all respondents[37].
‘I think something has got to go wrong sometime... I
think if I had diabetes I would be more worried.
I think it [heart attack] is quite a nice way to go-just
pop your clogs!’ [Project Manager, White British
male, 61, 6% risk, 20% threshold]
The information provided of risks and effectiveness of
treatment
The attitudes to the information presented did not
necessarily correspond to whether the respondents
understood the data, however, there were some trends
noted.
One respondent [Retired toolmaker, White British
male, 73, 11% risk, 3% threshold], who did not pass the
comprehension questions, said that he would ‘prefer to
know why’ and ‘as long as you’ve got the information to
look at, he can recommend it to you. After all, he is the
expert, you’re not. At least you’ve got some idea of
what’s likely to happen... To a lot of people my age, per-
centages don’tm e a nat h i n gt ot h e mb u tt h ew a yy o u
have presented it, it is so easy to find’. However, he
pointed out ‘looking at it from the doctor’sp o i n to f
view it would be time consuming and they are under
tremendous pressure’. The interviewer asked him ‘what
about from your point of view’ and he responded, ‘You
could do with something far simpler, if it was just the
doctor talking to me.’
One respondent [Retired factory processor, White
Irish male, 68, 11% risk, 3% threshold], who had also
failed the comprehension question stated that he
found the information irrelevant: ‘Ij u s tg oa l o n gw i t h
the doctor at all times. I’m not impressed with graphs
and figures.’ However, he also demonstrated an under-
standing that the information that was underpinning
medical practice was not straightforward: ‘Occasionally
they are wrong because doctors differ and patients
die’.
Others (who all passed the comprehension questions)
liked the idea of joint decision making:
‘I do understand the statistics that are shown... and it
is like making a joint decision, otherwise [you’d] just
leave it to the doctor. It’s like a team... I like the sta-
tistics.’ [Clothing wholesaler running own business,
Asian Indian male, 48, 2% risk, > 30% threshold]
‘It makes you feel that you’re doing something for
yourself and you’re helping yourself and it’s more or
less your decision as well. You’re not in someone
else’sh a n d s . ’ [Retired labourer in building trade,
White Irish male, 69, 6% risk, 3% threshold]
‘Most professional people are experts in their own
field so you have to be led by them but you don’t
have to be led blindly, do you?’ [Retired sales man-
ager, White British male, 65, 8% risk, 3% threshold]
Some were very critical of the use of the findings on
the level of benefit of the preventative treatment to jus-
tify putting people on medication. These responses echo
the concerns of some clinicians in our sample (see
below). The first three of these critical voices came from
patients who passed the comprehension questions; the
final one had not passed the questions.
‘I would need to have a very obvious benefit [of tak-
ing preventative medication] to persuade me to do
anything about it now.’ [Retired electrical draftsman,
White British male, 72, 13% risk, > 30% threshold]
’With a low improvement rate I felt that isn’tr e a l l y
worth the inconvenience of taking the tablets’
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male, 65, 7% risk, > 30% threshold.
‘I think it is silly because 6% is hardly anything. If...
the doctor said well I think you’d better have surgery
because chances of coming out are 6%... It’sav e r y
small percentage you know.’ [Clothing wholesaler
running own business, Asian Indian male, 48, 2%
risk, > 30% threshold]
‘Simple information such as a difference of 2% well
it’s not worth having the patient worry about it. I
suggest the doctor doesn’t tell the patient until it
gets to a percentage where the difference counts and
I think that is about 15, 20, 30 going up that way. I
think the figures will worry the patient more unne-
cessarily’ [Security guard, White British male, 60.
11% risk, 15% threshold]
F o rs o m e ,t h i sw a r i n e s sw a sr e i n f o r c e db yal a c ko f
faith in research findings, due to a mistrust of academia
and/or the pharmaceutical industry. The first of these
quotes comes from a respondent who was not asked the
comprehension questions; the second had not answered
them correctly. Both had previously stated that they
would accept treatment at the lowest level of risk.
‘Well I’m giving money or someone is giving money
to the big pharmaceutical companies and that’sa l l
they are interested in-making money. Whether the
things are suitably made, properly made and all that,
I’mn o ts u r ea b o u t . ’ [Retired Civil Servant, White
British female, 71, 10% risk, 3% threshold]
‘Well if you’ve been given information, it can be false
I think. I think people are chancing their arms
sometimes you know, with all these Professors and
research, I think that on occasion they are wrong
and it makes you a bit dubious you know so in my
case I am going with the tried and trusted.’ [Retired
factory processor, White Irish male, 68, 11% risk, 3%
threshold]
GP attitudes to preventative medication
Most of the GP respondents (n = 10) had a balanced
attitude to prevention of CVD, usually stating that life-
style changes were the preferred place to start to sup-
port prevention or indicating that the two things needed
to happen alongside each other. Many of these drew on
the language of concordance to support their views. As
one GP explained,
‘I try to have a discussion with people to find out
how much they want to use lifestyle modification
and I think in situations it is very important to have
the patient try the lifestyle to see if it will work and
then treat them, to give them the option... I try to
determine their preferences’.[ G P ,W h i t eB r i t i s h
male, 44, prescribe at 20% threshold].
Two of the GPs expressed grave concerns about the
value of preventative medication, citing side effects and
the wastage as the key reasons for this.
‘My view is that statins are greatly over rated, that
the numbers needed to treat (NNT)... of the best
trials is effectively equivalent to saying that 95% of
treatment with statins is wasted-95%-this is a scandal
which is fuelled by the interests of the pharmaceuti-
cal industry and the vested interests of the medical
profession... [this is] an enormous cost to the tax-
payer...Now one of the problems... is the new con-
tract which is extremely unethical because... people
who prescribe these medications will earn more
which is very sickening.’ [GP, Asian Indian male, 43,
prescribe at > 30% threshold].
Only one doctor [GP, Asian Indian male, 62, prescribe
at 3% threshold] said that he would always recommend
preventative medication to their patients, saying ‘Id o n ’t
take the slightest risk with someone else’sl i f e ’ but also
(as discussed further below) said that he would only
ever take curative medication himself.
GP attitudes to accepting preventative medication
themselves
Asking GPs if they would accept preventative medica-
tion themselves, if their risk score was above the cut-off
that they had indicated that they would use for their
patients, produced mixed results. A few stated that they
would accept the same levels of risk as their patients,
but the majority were keen to ‘try very hard the lifestyle
modification before getting into any drugs’ [GP, White
British male, 44, prescribe at 20% threshold]. One who
had indicated that they were anti-medication, stated that
they ‘practice what I preach’ and so went to the gym
regularly to stay fit, they added, ‘Its really a small chance
of these poisons helping so I won’tt a k et h e m ’ [GP,
Asian Indian male, 43, prescribe at > 30% threshold],
while another stated ‘If it is for prevention, I would not
take any medication’ [GP, Asian Indian male, 59, pre-
scribe at 3% threshold]. Some talked about their indivi-
dual risk scores and emphasized that all decisions would
depend on individual cases, such as ethnicity and family
history. A number dodged or refused to answer the
question. For instance:
‘I think that is a different question. I would say that
is a general point, personally I have not had my cho-
lesterol tested. My personal views are that I don’t
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never have, but I don’t think you need the thing of
the doctor not smoking, exercising etc in order to
give advice to people’ (GP, White British male, 56,
prescribe at 15% threshold].
For the doctor mentioned in the previous subsection,
who was supportive of preventative medication for his
patients, said ‘Myself it is different, we treat patients
more medically than we treat ourselves... Pain and dis-
ability would need to be there before I would take
drugs.’ [GP, Asian Indian male, 62, prescribe at 3%
threshold].
GP attitudes to guidelines and targets/erosion of
professional autonomy
Although we did not specifically ask for their views on
policy or targets, in a number of interviews, the issue
emerged spontaneously. In general, those who men-
tioned this were concerned that CVD and other chronic
diseases were ‘an epidemic’ a n df e l tt h a tt h et a r g e t sf o r
reducing heart disease were either ‘unrealistic’ or that
the policy was inappropriately focused on medication
rather than lifestyle change. One GP explained:
‘I feel that prevention is the ideal and whether you
treat something with acupuncture, homeopathy or
whatever the whole idea really is that the person
need to get their act together... smoking, obesity,
lack of exercise, I think this is far more important
than the goal at the moment, the protocol, which is
very much prescribing medication’ [GP, White Brit-
ish male, 52, prescribe at > 30% threshold].
‘I think patients need to take responsibility for their
lifestyle rather than rely on the doctors to treat the
problems’ (GP, Middle Eastern male, 55, prescribe at
30% threshold].
Another GP shared his strong beliefs on the ethics of
the Quality Outcomes Framework (QOF) and the Gen-
eral Medical Services (GMS) contract:
‘One of the problems is the new contract which is
extremely unethical because there is an incentive for
doctors to prescribe these... people who prescribe
these medications will earn more which is very sick-
ening... My philosophy... is, very simply, consensual
prescribing.’ [GP, Asian Indian male, 43, prescribe at
> 30% threshold].
Discussion
The unique contribution of this paper is related to the
discussion of attitudes to decision making after receiving
detailed and balanced information about the risks and
benefits of preventative treatment for CVD. Two princi-
pal findings emerge: first, about whose decision it is to
commence treatment and, second, what role the infor-
mation plays in that decision.
Deciding to medicate or not: whose decision is it?
The issue of preventative medication, both amongst the
patient and clinician population, is clearly controversial
[38-44] and our findings reflected this through the
diversity of responses; indeed, many responses directly
contradicted others. Both groups expressed some con-
cerns about medication and generally there was a pre-
ference for lifestyle changes, although a significant
minority of both patients and GPs expressed extreme
views either for or against prescribing medication.
Where patients expressed clear favourable or unfavour-
able views, in principle, to preventative medication,
these did not show a clear correspondence to the risk
thresholds at which they said they would accept medica-
tion. To compound this, the overwhelming majority of
patients said that, in the final instance, they would do
whatever the doctor recommended. Interestingly, how-
ever, the trust that patients showed in their GP’so p i -
nion was not extended beyond that personal
relationship.
Patients’ confidence in their GPs’ judgements con-
trasted with their distrust of distant or unfamiliar infor-
mation sources. Both GPs and patients indicated
concern about other interested parties (academics, phar-
maceutical industry and guideline authors) trying to
influence their decision-making. There is a literature on
‘disease mongering’ [45] which may help explain this
attitude. For the GPs, these trends may also be related
to threats to their professional autonomy. Many patients
expressed significant concerns or scepticism about the
value of preventative medication. These concerns were
also well represented amongst the clinicians, reflecting
wider debates in the medical profession on statins and
other drug treatments, such as aspirin [46].
For some GPs, there is a striking discordance between
prescribing for their patients and preferring lifestyle
changes for themselves. The assumptions and values
that underlie GPs’ decisions to treat patients more
medically than they would themselves bear further
investigation in future studies. However, it is important
to point out that there may be few satisfactory alterna-
tives. There is little evidence to suggest that lifestyle
advice has any significant effect [47] although it is worth
noting that it is difficult to design a rigorous trial to
evaluate this kind of intervention.
This study was limited by its location in one urban area
of the UK (both ethnically and economically diverse) and
both patients and GPs from other geographical regions
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majority of our sample were men (both the GPs and
patients), and while this reflects the demographics of the
local GP population and the population at risk of CVD, it
would be useful in future to explore women’sp e r s p e c -
tives more thoroughly. It would be of interest to explore
quantitatively the relationship between GP attitudes to
preventative medication and prescribing rates in their
practice.
The role of information in the decision making process
Despite providing participants with detailed descriptions
and visual representations of risks and benefits of treat-
ment, the data collected did not provide evidence to sup-
port a direct relationship between the information and
the outcome of decision-making. This adds a new dimen-
sion to the existing literature. It has long been argued
that clinicians’ decisions are influenced by the way in
which numerical information is framed. Clinicians are
more likely to offer treatment when benefits expressed as
relative risk reductions than absolute risk reductions
[48-50]. Similar observations about relative risks have
been made in relation to patients’ preferences [51].
Patients are also more persuaded to take treatment when
effects of treatment are framed in terms of reduced
potential losses (fewer adverse events or deaths) rather
than potential gains (higher chance of healthy survival).
Better understanding of information is associated with a
greater caution in relation to taking treatments. The
information we provided (described above) balanced
these potential biases. While patients largely welcomed
the information, because they felt more involved, they
were quite clear that it did not affect whether they would
accept treatment. They would accept the doctor’s recom-
mendation. It could be reasonably hypothesized that this
feeling of involvement would increase adherence over
time to treatment, but this was beyond the scope of our
study. It would be interesting to conduct a longitudinal
study to track whether the modes of communication of
risk information and the prescribing decision (including
commitments to any lifestyle changes) were maintained
over time. In addition, this kind of study might be very
useful to repeat as new approaches are developed to pro-
vide information to patients on any condition and its
treatments.
Conclusions
The tendency for patients to comply with doctors’ deci-
sions, even when they are not in line with their own pre-
ferences [52] is a significant concern in decision making
around starting preventative medication. Doctor-patient
communication about drugs is not always effective [53]
and it is common to find misunderstanding between
patients and their GPs about preferences for and
experiences of medicine taking [54]. This study under-
lines the responsibility of general practitioners to ensure
that they are acting in the patient’s best interests,
although there remains an outstanding potential conflict
between adhering to national guidelines and prioritising
patient’s preferences. Our findings showed that however
clearly the information was presented, there was still
some confusion between preventive and curative medica-
tion. This may be the result of a culturally-informed
assumption that medicine primarily has a curative role. It
is important that the patient understands what preventa-
tive medicine is and that it is possible that it may make
no difference to whether or not they suffer from heart
disease. Providing basic information about risks and ben-
efits can help with this, yet the GP’s recommendations
are the most influential factor in patient decision making.
However, although trusted by their patients, GPs see
themselves as subject to pressure from other sources.
Although it is beyond the scope of our study, it is also
worth noting that although patients may agree to being
put on medication at the consultation, they may then not
adhere to treatment long term [10,55].
Incentive payments such as those introduced to UK
general practice in the Quality and Outcomes Frame-
work of 2004 are an added complication. Payments to
practices are linked to achievement of blood pressure
targets in hypertensive and diabetic patients and coron-
ary heart disease patients receiving specific preventive
drugs such as aspirin, statins, angiotensin converting
enzyme inhibitors and beta-blockers. There is an impli-
cit tension between patient choice and achieving targets
and GPs seem to be more willing to follow recommen-
dations when deciding for their patients than when
deciding for themselves. Calls for doctors to engage in
partnership decision-making around preventative medi-
cation may be idealistic at this time [23]. Our findings
have starkly indicated that, as in the screening debate,
the interests of the whole population, and the interests
and preferences of particular individuals may not be the
same. At a clinical level, however, decision making must
clearly be on a case-by-case basis, taking into account
the social and cultural context in which the patient may
have to integrate tablet taking, their medical history and
their preferences.
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